Table 2.
Recommended universal varicella vaccination programs of different countries
| Country | Vaccine | Strain | Dose | 1st and 2nd dose introduction (yr) | Schedule (1st, 2nd dose) | Coverage (%) | |
|---|---|---|---|---|---|---|---|
| Western Pacific | 7 out of 27 member countries adopted (26%) | ||||||
| Australia | Varicella, MMRV | Oka | 1 | 2005 | 18 mo | 90% [30] | |
| Hong Kong | Varicella, MMRV | Oka, MAV | 2 | 2014 | 12 mo, 6 yr | 73% [51] | |
| Japan | Varicella | Oka | 2 | 2014 | 12–15 mo, 18–23 mo | 40% [32] | |
| New Zealand | Varicella | Oka | 1 | 2017 | 15 mo | - | |
| Niue | Varicella | - | 1 | 2017 | 15 mo | - | |
| South Korea | Varicella | Oka, MAV | 1 | 2005 | 12–15 mo | 96.3% [17] | |
| Taiwan | Varicella | Oka | 1 | 2004 | 12–18 mo | 98.6% [31] | |
| Europe | 14 out of 53 member countries adopted (26%) | ||||||
| Andorra | Varicella | Oka | 2 | No data | 15 mo, 3 yr | - | |
| Austria | Varicella | Oka | 2 | 2010 | 12–23 mo (4–wk interval) | - | |
| Cyprus | Varicella | Oka | 2 | 2010 | 13–18 mo, 4–6 yr | - | |
| Finland | Varicella, MMRV | Oka | 2 | 2017 | 18 mo, 6 yr | - | |
| Germany | Varicella, MMRV | Oka | 2 | 2004, 2009 | 11–14 mo, 15–23 mo | 1 dose 89.6% [52], 2 dose 75.3% [52] | |
| Greece | Varicella | Oka | 2 | 2006, 2009 | 12–15 mo, 2–3 yr | 1 dose 90% [53], 2 dose 75% [53] | |
| Hungary | Varicella | Oka | 2 | 2019 | 13 mo, 16 mo | - | |
| Iceland | Varicella | Oka | 2 | 2020 | 12 mo, 18 mo | - | |
| Israel | Varicella, MMRV | Oka | 2 | 2008 | 12 mo, 6–7 yr | - | |
| 12 m, 6 yr | - | ||||||
| Italy | Varicella, MMRV | Oka | 2 | 2017 | 13–15 mo, 6 yr | 84%–95% [54] | |
| Latvia | Varicella | Oka | 2 | 2008, 2019 | 12–15 mo, 7 yr | - | |
| Luxembourg | MMRV | Oka | 2 | 2009 | 12 mo, 15–23 mo | 1 dose 94.5% [35], 2 dose 83.3% [35] | |
| Spain | Varicella | Oka | 2 | 2016 | (National) 15 mo; 2–4 yr | 4 regions | |
| (Navarra) 15 mo; 3 yr | 1 dose 95% [3], 2 dose 86.1% [3] | ||||||
| Turkey | Varicella | Oka | 1 | 2013 | 12 mo | 60.1% [43] | |
| Americas | 17 out of 35 member countries adopted (49%) | ||||||
| Antigua | Varicella | Oka, MAV | 1 | 2014 | 24 mo | - | |
| Argentina | Varicella | Oka, MAV | 1 | 2015 | 15 mo | 74% [55] | |
| Bahamas | Varicella | Oka, MAV | 2 | 2012 | 12 mo, 4–5 yr | - | |
| Barbados | Varicella | Oka, MAV | 1 | 2012 | 12 mo | - | |
| Bermuda | Varicella | Oka, MAV | 1 | 2012 | 24 mo | - | |
| Brazil | MMRV, Varicella | Oka, MAV | 2 | 2013, 2018 | 15 mo, 4 yr | ≥80% [56] | |
| Canada | Varicella, MMRV | Oka | 2 | 2000–2007 (1 dose), 2011 (2 doses) | 12-15 mo, 18 mo | 93% [57] | |
| Cayman Islands | Varicella | Oka, MAV | 2 | 2000, 2009 | 12 mo, 3–6 yr | - | |
| Colombia | Varicella | Oka, MAV | 2 | 2015, 2019 | 12 mo, 5 yr | - | |
| Costa Rica | Varicella | Oka, MAV | 1 | 2007 | 15 mo | 95% [58] | |
| Ecuador | Varicella | Oka, MAV | 1 | 2010 | 15 mo | - | |
| Panama | Varicella | Oka, MAV | 2 | 2014, 2018 | 15 mo, 4 yr | - | |
| Paraguay | Varicella | Oka, MAV | 1 | 2013 | 15 mo | - | |
| Peru | Varicella | Oka, MAV | 1 | 2018 | 12 mo | - | |
| Puerto Rico | Varicella | Oka, MAV | 2 | 1996, 2007 | 12 mo, 4–6 yr | - | |
| United States of America | Varicella, MMRV | Oka | 2 | 1995, 2006 | 12–15 mo, 4–6 yr | 90% [59] | |
| Uruguay | Varicella | Oka, MAV | 2 | 1999, 2014 | 12 mo, 5 yr | 96% [60] | |
| Eastern Mediterranean | 6 out of 21 member countries adopted (29%) | ||||||
| Bahrain | Varicella | 2 | 2015 | 12 mo, 3 yr | - | ||
| Kuwait | Varicella, MMRV | 2 | 2017 | 12 mo, 24 mo | - | ||
| 12–24 mo, 12 yr | - | ||||||
| Oman | Varicella | 1 | 2010 | 12 mo | - | ||
| Qatar | Varicella | Oka | 2 | 2007 | 12 mo, 4–6 yr | 92% [42] | |
| Saudi Arabia | Varicella | 2 | 2008 | 18 mo, 4–6 yr | - | ||
| United Arab Emirates | Varicella | 2 | 2012 | 12 mo, 5–6 yr | 94% [43] | ||
No African or Southeast Asian countries (47 and 11 members, respectively) have adopted universal varicella vaccination programs.